Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Nika Pharmaceuticals Q3 2026 Results: Net Loss of $13K, Loss Widens

Nika Pharmaceuticals, Inc. reported a net loss of $46,077 for the nine months ended September 30, 2026, compared to a loss of $39,309 in the prior year period. The company remains in a pre-revenue stage with a total stockholders' deficit of $343,705 and is primarily funded through loans from related parties.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-0.0-0.0
Net income-0.0-0.0
EPS (diluted, $ a share)$0.00$0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: NIKA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Nika Pharmaceuticals, Inc: key numbers

Share price
$0.3500Close, Nov 16
Market cap
$369M
Shares outstanding
1.05BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.